ARTICLE | Clinical News
Imbruvica ibrutinib regulatory update
January 19, 2015 8:00 AM UTC
FDA assigned an April 17 PDUFA date to an sNDA from Pharmacyclics for Imbruvica ibrutinib to treat Waldenstrom’s macroglobulinemia. The Bruton’s tyrosine kinase (Btk) inhibitor is approved in the U.S....